Payment overview · 2025
General Payments
$260.26
12 reported records · 8 companies
Healthcare provider profile · identity verified
Shin W Kang
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1457411209
Verified facts
What the public records show
CMS Open Payments records show Shin W Kang received $260.26 in general payments during 2025 across 12 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.99 | 23.4% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.74 | 18.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.88 | 14.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.74 | 11.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.59 | 9.8% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $23.14 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.38 | 7.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.80 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.26 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.99 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.74 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1102 | 265 |
| Losartan Potassium | Losartan Potassium | 855 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 506 | 117 |
| Alendronate Sodium | Alendronate Sodium | 356 | 93 |
| Metformin Hcl | Metformin Hcl | 353 | 89 |
| Vascepa | Icosapent Ethyl | 347 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 333 | 84 |
| Creon | Lipase/Protease/Amylase | 280 | 82 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 279 | 92 |
| Finasteride | Finasteride | 234 | 60 |
| Donepezil Hcl | Donepezil Hcl | 207 | 56 |
| Icosapent Ethyl | Icosapent Ethyl | 184 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 44 |
| Glipizide Er | Glipizide | 170 | 41 |
| Januvia | Sitagliptin Phosphate | 163 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 40 |
| Simvastatin | Simvastatin | 151 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 35 |
| Meloxicam | Meloxicam | 130 | 74 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 52 |
| Memantine Hcl Er | Memantine Hcl | 116 | 35 |
| Tadalafil | Tadalafil | 102 | 28 |
| Cyclosporine | Cyclosporine | 99 | 32 |
| Gabapentin | Gabapentin | 98 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 26 |
| Azithromycin | Azithromycin | 95 | 79 |
| Ketoconazole | Ketoconazole | 95 | 33 |
| Tradjenta | Linagliptin | 90 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 24 |
| Nifedipine Er | Nifedipine | 81 | 18 |
| Memantine Hcl | Memantine Hcl | 79 | 22 |
| Eliquis | Apixaban | 77 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 77 | 18 |
| Sildenafil Citrate | Sildenafil Citrate | 77 | 22 |
| Baclofen | Baclofen | 71 | 31 |
| Temazepam | Temazepam | 70 | 23 |
| Dutasteride | Dutasteride | 68 | 13 |
| Jardiance | Empagliflozin | 66 | 12 |
| Levofloxacin | Levofloxacin | 64 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 15 |
| Atenolol | Atenolol | 61 | 13 |
| Labetalol Hcl | Labetalol Hcl | 58 | 11 |
| Ciclopirox | Ciclopirox | 55 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Omeprazole | Omeprazole | 48 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 13 |
| Restasis | Cyclosporine | 42 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | 15 |
| Farxiga | Dapagliflozin Propanediol | 39 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 21 |
| Ibuprofen | Ibuprofen | 33 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 24 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 20 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 14 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.26 · 12 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, KISUNLA, Kerendia, LEQVIO, LOREEV XR, PANCREAZE, Repatha, SHINGRIX, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error